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Abstract
Title: Intraoperative Ketamine to Reduce Postoperative Opioid Consumption in Chronic Pain
Patients
Background: Typically, chronic pain patients have a predisposition for higher postoperative
pain rating and a slower resolution of this pain. Ketamine, a potent anesthetic agent, works to
inhibit the N-Methyl-D-aspartate (NMDA) receptors causing dissociative anesthesia. The
NMDA receptors contribute to the pain felt after tissue injury and can cause increased pain
perception. Ketamine binds to the NMDA receptors and blocks this effect reducing the patient’s
pain postoperatively.
Purpose: The purpose of this literature search is to provide an extensive review of the literature
regarding ketamine administration and its effect on reducing postoperative pain and opioid
requirements.
Process: A literature review was conducted using the PubMed, CINAHL, and Cochrane library
databases which were accessed through the University of North Dakota’s Health Sciences
Library. Other pertinent literature was obtained by searching the reference lists of initially
acquired articles. All research was evaluated extensively and applied to this paper or rejected due
to substandard information.
Results: A review of the literature revealed case reports that supported the use of sub-anesthetic
doses of ketamine for the purpose of reducing postoperative opioid consumption. Overall, the
studies showed consistency between intraoperative ketamine administration and decreased
opioid use and pain levels immediately following surgery. This was found to be consistent for
patients with and without chronic pain.

INTRAOPERATIVE KETAMINE AND POSTOPERATIVE OPIOID USE
Implications: Based upon the data compiled throughout this literature review one practice
recommendation is definite: the administration of intraoperative sub-anesthetic doses of
ketamine should be used as an adjunct for general and regional anesthesia to decrease
postoperative pain.
Keywords: ketamine, postoperative, chronic pain, perioperative, opioid use and surgical
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Intraoperative Ketamine to Reduce Postoperative Opioid Consumption in Chronic Pain Patients
Chronic pain is an epidemic in the United States, resulting in an increased number of
prescribed opioids. As a result, medical professionals are being encouraged to decrease opioid
prescriptions. Surgical pain often requires opioid administration for relief. Studies have shown
that many patients who have been diagnosed with chronic pain are prescribed an opioid for pain
relief. According to a study completed by Chapman, Davis, Donaldson, Naylor & Winchester
(2011), chronic pain patients, in general, have a predisposition for higher postoperative pain
rating and a slower resolution of this pain. The study states that chronic pain patients who have a
surgical procedure and are currently prescribed an opioid experience markedly higher
postoperative pain. Therefore, it is important for anesthesia providers to effectively manage
postoperative pain in this patient population.
Ketamine was synthesized in 1962 from a series of phencyclidine derivatives (Mion,
2017). Researchers found it to be an excellent anesthetic that was short-acting and, unlike its
phencyclidine precursors, the side effects were less potent and better tolerated (Mion, 2017). In
1964, ketamine use in humans was first attempted (Mion, 1017). Ketamine was patented in 1966
for human and animal use and officially approved for human use by the United States Food and
Drug Administration in 1970. It was used as a field anesthetic during the Vietnam War. In 1971,
subanesthetic doses of ketamine were shown to have analgesic properties with moderate side
effects (Mion, 2017). Subanesthetic dose or “low-dose” ketamine is defined as a bolus of <
1milligram/kilogram (mg/kg) intravenous or a continuous intravenous infusion < 20
micrograms/kilogram/minute (mcg/kg/min) (Kaur, S., Saroa, R., & Aggarwal., 2015).
Ketamine, a potent anesthetic agent, works to inhibit the N-Methyl-D-aspartate (NMDA)
receptors causing dissociative anesthesia (Vargo, 2012). The NMDA receptors contribute to the
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pain felt after tissue injury and can cause increased pain perception (Vargo, 2012). Ketamine
binds to the NMDA receptors and blocks this effect reducing the patient’s pain postoperatively
(Nagelhout & Plaus, 2014). Intraoperative ketamine use has been shown to reduce morphine use
by 52% in the 48 hours following surgery (Vargo, 2012). According to Himmelseher and
Durieux (2005), ketamine may also prevent opiate tolerance, allowing for smaller doses of
opioids to be more effective. Ketamine’s usefulness in the perioperative setting is promising, as
it has been shown as an analgesic, anesthetic, and to decrease opioid requirements.
Purpose
The purpose of this independent project is to present a case report and provide anesthesia
providers with evidence-based research regarding the effect of intraoperative ketamine on postoperative pain in the adult patient with chronic pain. Understanding the pharmacology of
ketamine and the pathophysiology of chronic pain will enable anesthesia providers to make
informed decisions regarding perioperative pain management.
Case Report
A 28-year-old, 99 kilogram, 160 centimeter female presented for a diagnostic
laparoscopy. Past medical history included ovarian cyst and chronic pelvic pain. Past surgical
history included cholecystectomy, cervix biopsy, colposcopy and ovarian cystectomy. The
patient had an allergy to ketorolac and morphine, both of which caused a rash. Home
medications included acetaminophen, ibuprofen, and naproxen. There was no history of
anesthetic complications. Pre-operative vital signs were: blood pressure 126/82 mmHg, heart rate
83 beats per minute (BPM), respiratory rate 18/minute, temperature 36.7 degrees Celsius, and
oxygen saturation 99% on room air. Pre-operative laboratory data included a negative urine
pregnancy. An airway assessment revealed a Mallampati classification II pre-operatively, a
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thyromental distance of fewer than three fingerbreadths, and full neck range of motion. The
patient was given an American Society of Anesthesiologists physical status class II.
The patient was transported to the operating room (OR). Upon arrival to the OR, she was
given 2 milligrams (mg) midazolam intravenously (IV). She was then assisted onto the operating
table per OR staff. Standard monitors were applied, including a blood pressure cuff, pulse
oximetry, and 5-lead EKG. Vital signs were stable.
The patient was pre-oxygenated via facemask with 100% oxygen. The patient was then
induced intravenously through a 20-gauge intravenous catheter with 100 micrograms (mcg) of
fentanyl, 60 mg lidocaine, 200 mg propofol, 60 mg rocuronium and 50 mg ketamine. A 7.0 mm
cuffed endotracheal tube (ETT) was placed by direct laryngoscopy utilizing a Miller two blade.
After intubation, tube placement was confirmed by bilateral breath sound auscultation, the
presence of end-tidal carbon dioxide, and condensation within the tube. The tube was secured at
21 cm at the lip. The patient was placed on the ventilator on pressure controlled ventilationvolume guarantee mode with a respiratory rate of 10 breaths per minute, a tidal volume of 550
milliliters and positive end-expiratory pressure of 8 cm/H20. The anesthetic was maintained with
sevoflurane with end-tidal concentrations of 1.8-2.4% throughout the case. A nasopharynx
temperature probe was inserted for temperature monitoring, and a bispectral index monitor was
applied to the forehead to monitor anesthetic depth.
Following induction, the patient was placed in supine position with arms tucked and
pressure points padded. The patient received 2 grams of cefazolin IV prior to incision for post
operative infection prophylaxis. Six mg of dexamethasone and 4 mg of ondansetron were given
intravenously to prevent post-operative nausea and vomiting. A ketamine infusion was initiated
at 10mcg/kg/min prior to incision. Another 100 mcg of fentanyl IV was given just prior to
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incision for anticipated discomfort. Intra-abdominal pneumoperitoneum was established, and the
patient was placed in Trendelenburg position. During the maintenance phase, the patient received
1200 milliliters of lactated ringers. No further fentanyl was administered during the case. Blood
loss was estimated to be less than 50 milliliters. The non-depolarizing muscle relaxant was
reversed with 0.6 mg of glycopyrrolate IV and 3 mg of neostigmine IV. The patient was
extubated awake in the OR without difficulty.
The patient was transported to the post-anesthesia recovery unit (PACU). While in the
PACU, the patient required an additional 75 mcg fentanyl intravenously. She was discharged
home with a stated pain level of 1/10 to the abdomen and a prescription for oral 5 mg
hydrocodone/325 mg acetaminophen.
Literature Search
According to Stillwell, Fineout-Overholt, Melnyk, and Williamson (2010), a literature
search to answer a research question should be done using the Cochrane Library, PubMed and
CINAHL databases as these will result in the strongest level of evidence. For this literature
search, the Cochrane library, PubMed and CINAHL databases were accessed via the University
of North Dakota’s Health Sciences Library. The Cochrane Library, PubMed, and CINAHL
databases were utilized because they contain medical, scientific, and nursing literature (Stillwell
et al., 2010).
Keywords and Limits
Within the PubMed database, one search was conducted using Medical Subject Heading
(MeSH) terms and the PubMed search builder. Using MeSH terms makes a search allencompassing by finding all articles related to the concept. The first search utilized the MeSH
term “ketamine.” In the search results, there were several subheadings. From the subheadings,
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therapeutic use was added to the PubMed search builder. The second search included the term
“chronic pain,” which yielded several more subheadings. From these subheadings, “prevention
and control” was added to the PubMed Search builder. This resulted in eight articles. Five of
these articles were specifically pertinent to the topic of interest.
The CINAHL database was searched next utilizing the CINAHL headings option for a
more effective search. CINAHL headings are similar to MeSH terms in the PubMed database.
The terms “ketamine” and “postoperative” were used resulting in 133 articles. To further narrow
the results down to pertinent articles, the term “chronic pain” was added, which resulted in seven
relevant articles. One final search was conducted in the CINAHL database utilizing the terms
"chronic pain," "postoperative," and "opioid use." This search resulted in seven articles.
The terms “ketamine” and “chronic pain” were searched under the “title, abstract,
keywords” on the Cochrane database resulting in six articles relevant to this topic. One final
search in the Cochrane database utilizing the terms “ketamine” and “perioperative” resulted in
three pertinent articles.
Additionally, three applicable articles were found by reviewing the reference list of
research articles that had already been evaluated. The identification of key search terms as well
as the use of controlled vocabulary within credible healthcare focused databases proved to be an
effective and efficient literature search strategy.
After searches within the CINAHL and PubMed databases were completed, a total of 13
articles were saved and reviewed. A review of the literature will be presented in the following
section.
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Review of Literature
To evaluate the research on intraoperative ketamine use to decrease postoperative opioid
requirements in chronic pain patients it is imperative to know and understand the pharmacology
of ketamine and pathophysiology of chronic pain. The literature on these topics will be discussed
first, followed by the role of ketamine in chronic pain.
Pain Physiology
According to the International Association for the Study of Pain, pain is defined as “an
unpleasant sensory and emotional experience associated with actual or potential tissue damage”
(Steeds, 2016). Pain is a subjective experience that results from both physical and psychological
responses to injury and is difficult to measure (Steeds, 2016). It is the result of a complex
interchange between signaling systems, modulation from higher centers, and the individual's
unique perception (Steeds, 2016). According to Nagelhout and Plaus (2014), pain can be
classified based on duration (acute or chronic) or underlying pathophysiology (nociceptive or
non-nociceptive). Nociceptive pain is further differentiated into somatic or visceral pain. There
are four processes associated with nociceptive pain: transduction, transmission, perception, and
modulation. Non-nociceptive pain breaks down into neuropathic or idiopathic pain (Nagelhout &
Plaus, 2014).
Acute pain.
Acute pain occurs due to a traumatic injury, surgery or acute illness, and the noxious
stimulation it causes (Nagelhout & Plaus, 2014). It usually resolves as healing occurs and is
responsive to pharmacological intervention and treatment of the underlying cause (Nagelhout &
Plaus, 2014). It is often associated with nociceptive pain and begins with nociceptors (Nagelhout
& Plaus, 2014).
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Nociceptors are receptors in tissues specific to painful stimuli (Steeds, 2016). Activation
of nociceptors initiates signaling systems (Steeds, 2016). The signaling systems transduce the
noxious information into an electrical signal and send it to the central nervous system (Steeds,
2016). Nociceptors can be differentiated into two types: high-threshold mechanoreceptors and
polymodal nociceptors (Steeds, 2016). High-threshold mechanoreceptors respond to mechanical
deformation, while polymodal nociceptors respond to an array of mediators including hydrogen
ions, cytokines, bradykinin, histamine, prostaglandins and leukotrienes (Nagelhout & Plaus,
2014; Steeds, 2016). These mediators activate and sensitize nociceptors. Nociceptors transmit
their information along two types of nerve fibers: A-delta and C (Steeds, 2016). All pain fibers
terminate in the dorsal horn, C fibers in lamina II (the substantia gelatinosa) and A-delta fibers in
laminae I and V (Steeds, 2016). In these laminae, the A-delta and C fibers synapse with secondorder neurons (Steeds, 2016).
Second-order neurons break down into three types: nociceptive specific, wide dynamic
range and low threshold (Steeds, 2016). Nociceptive-specific second-order neurons respond
selectively to high-threshold noxious stimuli and are found in laminae II and III (Steeds, 2016).
Wide dynamic range second-order neurons respond to a variety of sensory stimuli and are
located in laminae V and VI (Steeds, 2016). Low-threshold second-order neurons respond solely
to innocuous stimuli (Steeds, 2016). These neurons cross the midline of the spinal cord and
ascend in the anterolateral pathway of the spinothalamic tract to the thalamus where they then
synapse with third-order neurons (Steeds, 2016). Third order neurons send projections to the
cerebral cortex (Steeds, 2016). The pain signal is sent to the amygdala, the somatosensory areas
of the cortex, the hypothalamus and the anterior cingulate cortex (Nagelhout & Plaus, 2014).
These areas play various roles in the perception of pain (Nagelhout & Plaus, 2014).
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Suppression of pain occurs through local inhibitory interneurons and descending efferent
pathways (Steeds, 2016). Two important areas of the brainstem are involved in reducing pain,
which is the final process of nociceptive pain, the periaqueductal grey, and the nucleus raphe
magnus (Steeds, 2016). The periaqueductal grey surrounds the cerebral aqueduct in the midbrain
and when stimulated, produces profound analgesia (Steeds, 2016). Anti-nociceptor neurons in
the periaqueductal grey excite cells in the nucleus raphe magnus that then project down the
spinal cord and block pain transmission by dorsal horn cells (Steeds, 2016). The nucleus raphe
magnus consists of serotonin-containing neurons that, when stimulated, produces analgesia and
block pain transmission (Steeds, 2016). Several neurotransmitters contribute to the inhibitory
modulation of pain; these include enkephalin, glycine, norepinephrine, serotonin and gammaaminobutyric acid (Nagelhout & Plaus, 2014).
Chronic pain.
Chronic pain is defined as pain that lasts longer than three months or beyond the normal
healing time of an injury (Nagelhout & Plaus, 2014). The transition to chronic pain from acute
pain occurs when peripheral damage and tissue inflammation switch to more prominent central
nervous system mechanisms. Chronic pain is associated with peripheral and central sensitization.
As previously described, in response to noxious stimuli, allogenic substances and
neurotransmitters are released and enhance excitability of nerves. Constant excitation of these
nerves can reduce pain thresholds and cause hyperalgesia. This process is termed peripheral
sensitization (Nagelhout & Plaus, 2014).
Changes can also occur directly to nerve endings when nerve injury is present. These
changes include the sprouting of new hyperexcitable nerve endings which fire ectopically or the
formation of a neuroma, causing abnormal mechanosensitivity (Nagelhout & Plaus, 2014).
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Regenerated and damaged nerves also have reduced thresholds, rendering them responsive to
non-noxious stimuli (Nagelhout & Plaus, 2014).
Chronic pain is associated with chronic inflammation (Reddi & Curran, 2014). This
chronic inflammation causes hyperexcitability and sensitization of second-order neurons in the
dorsal horn (Reddi & Curran, 2014). Ongoing nociceptive input may cause an increase in
excitability of neurons in the central nervous system (Reddi & Curran, 2014). This is known as
central sensitization and may manifest as hyperalgesia or allodynia (Reddi & Curran, 2014). A
central mechanism in the spinal cord, called "wind-up," may occur with repeated, prolonged and
noxious stimulation (Reddi & Curran, 2014). Wind-up occurs with repeated activation of C
fibers and is due to the action of glutamate at NMDA receptors (Reddi & Curran, 2014). Due to
the ongoing nociceptive input, second-order neuron response to painful stimuli is amplified and
may outlast the initial stimulus, also contributing to hyperalgesia. This also lowers the pain
threshold outside the area of inflammation (Reddi & Curran, 2014).
Within the dorsal horn, inhibitory neurotransmitters are reduced, and excitatory synaptic
connections are strengthened (Steeds, 2016). Output to the spinothalamic tract is increased as
incoming axons develop ectopic activity (Steeds, 2016). This is all mediated via N-methyl-Daspartate, neurokinins and nitric oxide (Steeds, 2016). The end result is a lowered sensory
threshold and an enlarged receptive field (Steeds, 2016). Along with these excitatory
neurotransmitters, others such as substance P and calcitonin-gene-related peptide, bind to their
receptors and trigger up-regulation of second messengers (Nagelhout & Plaus, 2014). The upregulation of second messengers produces hyperexcitability of N-methyl-D-aspartate receptors,
also contributing to central sensitization and chronic pain (Nagelhout & Plaus, 2014).
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N-methyl-D-aspartate Receptors
N-methyl-D-aspartate (NMDA) receptors are glutamate-gated cation channels with high
calcium permeability (Nagelhout & Plaus, 2014). They are found at most excitatory synapses in
the post-synaptic membrane of a neuron (Mion & Villevieille, 2013). These receptors are present
on most cells of the central nervous system, especially those that participate in nociception
(Mion & Villevieille, 2013). They are involved in signal transduction, learning, memory
formation and pain (Mion & Villevieille, 2013). Full activation of NMDA receptors is both
voltage and ligand-gated (Nagelhout & Plaus, 2014). NMDA receptors can have any variation of
three different subunits; however, functional receptors are composed of two GluN1 and two
GluN2 or GluN3 subunits (Mion & Villevieille, 2013). These subunits contain four hydrophobic
segments in their central region, three of which are transmembrane with the fourth being the
ionic channel of the receptor (Mion & Villevieille, 2013). Each receptor has an extracellular
amino-terminal domain linked to an extracellular ligand binding domain (Vyklicky et al., 2013).
This is then connected to a transmembrane domain which forms the ion channel (Vyklicky et al.,
2013).
Activation of GluN1 and GluN2 subunits requires two molecules of glycine and two
molecules of glutamate (Vytlicky et al., 2013). Other co-agonists that act on these subunits are
D-serine, L-serine, D-alanine, and L-alanine (Vytlicky et al., 2013). Glutamate is the major
excitatory neurotransmitter in CNS (Nagelhout & Plaus, 2014). It activates NMDA receptors by
occupying two binding sites of GluN2 subunits (Vytlicky et al., 2013). Baseline glutamate levels
are maintained by a glutamate uptake system and prevent substantial NMDA receptor activation
at rest (Vytlicky et al., 2013). This leads to an influx of sodium and calcium and an efflux of
potassium, causing depolarization and action potential (Vytlicky et al., 2013). NMDA receptors
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are 5-10x more permeable to calcium than to sodium or potassium (Bennett, 2000). The influx of
calcium activates calcium-dependent enzymes and downstream signaling pathways. This can
lead to long-term changes in synaptic strength and cellular modifications (Zito & Scheuss, 2009).
NMDA channel closing is controlled by the rate of glutamate unbinding and receptor
desensitization (Zito & Scheuss, 2009).
Magnesium blocks NMDA receptor activation in a voltage-dependent manner (Nagelhout
& Plaus, 2014). At resting membrane potential, the receptor remains blocked (Nagelhout &
Plaus, 2014). With membrane depolarization, the magnesium block is relieved (Zito & Scheuss,
2009). At this time, any NMDA receptors with glutamate will open (Zito & Scheuss, 2009).
Coactivation of multiple synapses can overcome magnesium block (Zito & Scheuss, 2009).
NMDA receptor activation requires glutamate presence and binding along with depolarization of
postsynaptic membrane to unseat the magnesium (Bennett, 2000). Calcium influx into
postsynaptic cells activates signaling molecules in postsynaptic cells (Bennett, 2000).
Central sensitization occurs when glutamate released from C-nociceptors activate NMDA
receptors (Bennett, 2000). As previously discussed, activation of NMDA receptor by glutamate
released from C-fibers causes the spinal cord neuron to become more responsive to inputs,
including input from damaged or sensitized nociceptors and low-threshold mechanoreceptors,
contributing to the development of central sensitization and chronic pain (Bennett, 2000).
Excessive activation of NMDA receptors leads to excitotoxic cell death and plays a crucial role
in many acute and chronic neuro disorders (Vyklicky et al., 2013).
NMDA receptor antagonists can act at the agonist binding site, within the ion channel
pore or at specific modulation sites (Vyklicky et al., 2013). Competitive antagonists compete
with the agonist for the binding site but do not activate the receptor (Vyklicky et al., 2013).
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Dissociative anesthetics act as a potent channel blocker (Vyklicky et al., 2013). Blockade of the
ion channel is voltage and use-dependent which means the block of the channel requires previous
receptor activation (Vyklicky et al., 2013). Inhibition by channel blockers is slow in onset and
increases with the probability of channel opening (Nagelhout & Plaus, 2014).
Phosphorylation with phosphatase protein type I and cAMP-dependent protein kinase at
the GluN1 subunit is responsible for long-term potentiation, hyperalgesia and opioid interactions
with the NMDA receptor (Mion & Villevieille, 2013). Opioid receptors have been found to cause
a dose-dependent activation of NMDA receptors on the surface of the same cells (Mion &
Villevieille, 2013). Phosphorylation of NMDA receptors decreases the magnesium plug and
calcium can enter the cell (Mioin & Villevieille, 2013). This leads to down-regulation and a
blunted response of opioid receptors (Mion & Villevieille, 2013).
Ketamine
Ketamine was synthesized by Calvin Stevens in 1962 out of phencyclidine derivatives in
search of the ideal anesthetic agent with analgesic properties (Mion, 2017). Phencyclidine was
initially studied but was found to cause severe excitation, to the point of unmanageable (Mion,
2017). In 1964, the first dose of ketamine was administered to humans by doctors Corssen and
Domino (Mion, 2017). This led to the first clinical study published in 1965, which described the
dissociative anesthesia associated with ketamine administration (Mion, 2017). Ketamine became
available in 1969 for human and animal use and officially approved by the United States Food
and Drug Administration in 1970 (Mion, 2017). However, widespread use of ketamine was
halted due to concerns about hallucinations and the arrival of Propofol on the market (Mion,
2017). Following the Vietnam War, ketamine abuse became a problem and ketamine was added
to the class III substances list (Mion, 2017).
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Much has been learned over the years through studies completed on ketamine, including
much of what is known about NMDA receptors and their various roles. Ketamine is now being
used to treat depression, as well as chronic pain (Mion, 2017).
Chemical make-up.
Ketamine is an arylcyclohexylamine derivative structurally related to phencyclidine
(Barash et al., 2017). The chemical structure of ketamine is 2-(O-chlorophenyl)-2(methylamino)cyclohexane hydrochloride (Nagelhout & Plaus, 2014). Ketamine contains a
chiral center at the C-2 carbon of the cyclohexanone ring, creating two enantiomers:
S(+)ketamine and R(-)ketamine (Barash et al., 2017). The S-enantiomer is more potent, has a
shorter duration of action, and is cleared more rapidly than the R-enantiomer (Barash et al.,
2017). Ketamine is a white crystalline powder that is partially water-soluble, slightly acidic with
a pH of 3.5 to 5.5 and 7.5 pKa. (Nagelhout & Plaus, 2014).
Pharmacokinetics.
Ketamine is bioavailable by intravenous, intramuscular, transnasal, rectal, and oral routes
(Barash et al., 2017). It is lipid soluble and not highly protein bound which allows for rapid
uptake in highly perfused areas first (Barash et al., 2017). The onset of action after intravenous
administration is 30 to 60 seconds and duration of 10 to 15 minutes (Barash et al., 2017).
Ketamine is redistributed from the central nervous system to the peripheral tissues in 11 minutes,
and total elimination from the body is 2.5 hours after intravenous administration (Barash et al.,
2017). Ketamine is metabolized by cytochrome P-450 enzymes by demethylation to norketamine
(Barash et al., 2017). Norketamine is one-third as active as ketamine (Barash et al., 2017).
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Mechanism of action.
Ketamine works on NMDA, opioid, noradrenergic, nicotinic and muscarinic receptors
(Miller et al., 2015). However, it is its non-competitive antagonist action on NMDA receptors
that are responsible for its main pharmacological properties (Miller et al., 2015). Ketamine binds
to an intrachannel site on the NMDA receptor referred to as the phencyclidine site (Miller et al.,
2015). This binding decreases channel opening time (Barash et al., 2017; Mion & Villevieille,
2013). Ketamine prevents "windup," especially if the NMDA receptor was already opened by
glutamate (Mion & Villevieille, 2013). It also works on a second site in the hydrophobic domain
of the NMDA receptor to decrease the frequency of channel opening (Miller et al., 2015). By
blocking these receptors, the medial thalamic nuclei, responsible for preventing afferent signals
of pain perception to the thalamus and cortex, is depressed (Nagelhout & Plaus, 2014). NMDAreceptor antagonists suppress central sensitization (Bennett, 2000).
Ketamine's action on noradrenergic neurons causes inhibition of catecholamine uptake
and leads to a hyperadrenergic state with increased release of norepinephrine, dopamine, and
serotonin (Mion & Villevieille, 2013). This inhibition leads to prolonged synaptic action and an
increased transfer of norepinephrine in the circulation (Mion & Villevieille, 2013). The hypnotic,
psychic and analgesic effects of ketamine are partly due to this action (Mion & Villevieille,
2013). Ketamine affects CNS cholinergic neurons (Mion & Villevieille, 2013). It also acts on
central nervous system cholinergic neurons by directly inhibiting nicotinic and muscarinic
receptors (Mion & Villevieille, 2013). Of the opioid receptors, ketamine binds to mu, delta, and
kappa but this is not believed to provide analgesia (Mion & Villevieille, 2013). The kappa opioid
receptor involvement may be responsible for some of the psychic effects seen with ketamine
(Mion & Villevieille, 2013).
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Ketamine causes "dissociative anesthesia” due to a functional dissociation between
thalamo-neocortical and limbic systems which allow sensory inputs to reach receiving areas but
fail to be observed (Mion & Villevieille, 2013). It depresses neuronal function in the cerebral
cortex and thalamus while simultaneously activating the limbic system (Mion & Villevieille,
2013).
Side effects and contraindications.
Ketamine affects the cardiovascular, central nervous, and respiratory systems (Nagelhout
& Plaus, 2014). It increases cerebral blood flow and the cerebral metabolic rate of oxygen, thus
increasing intracranial pressure (Nagelhout & Plaus, 2014). Because of this, ketamine is
contraindicated in patients with increased intracranial pressure (Nagelhout & Plaus, 2014).
Ketamine modifies electroencephalogram readings by decreasing alpha rhythm amplitude and
the appearance of theta waves (Miller et al., 2015). It has also been found to cause a dosedependent increase in the bispectral index (Nagelhout & Plaus, 2014). Due to its effects in the
central nervous system, patients will exhibit a cataleptic state with nystagmus and pupil dilation
(Miller et al., 2015).
Ketamine causes psychological reactions that may occur during awakening (Miller et al.,
2015). These are often manifested as vivid dreaming, hallucinations, and extracorporeal
experiences (Miller et al., 2015). They are secondary to depression of auditory and visual relay
nuclei that leads to misinterpretation of auditory and visual stimuli (Miller et al., 2015). The
incidence of these reactions can be reduced by administration of benzodiazepines (Miller et al.,
2015; Nagelhout & Plaus, 2014).
Ketamine preserves protective airway reflexes and has bronchodilatory activity
(Naglehout & Plaus, 2014). It has minimal effects on the central respiratory drive (Nagelhout &

INTRAOPERATIVE KETAMINE AND POSTOPERATIVE OPIOID USE

20

Plaus, 2014). It does cause lacrimation and salivation through its action on cholinergic receptors
(Nagelhout & Plaus, 2014).
Ketamine has cardiovascular stimulating effects related to direct stimulation of the
sympathetic nervous system, causing an increase in pulmonary and systemic blood pressure,
heart rate, and cardiac output, thereby increasing myocardial oxygen consumption (Miller et al.,
2015). According to Miller et al. (2015), cardiovascular stimulation occurs after small dose
ketamine infusion. Cardiodepression may also occur either pre-stimulation or post-infusion.
Cardiodepression may precede stimulation if a large dose of ketamine is administered. It may
also happen after repeated administrations when presynaptic catecholamine stores become
depleted. Post-infusion, cardiodepression may be seen if cardiac output drops below pre-infusion
cardiac output. Benzodiazepines may be helpful to prevent the stimulating effects (Miller et al.,
2015).
Other side effects seen include increased intraocular pressure, potentiation of
neuromuscular blocker and nausea and vomiting (Nagelhout & Plaus, 2014). According to Kaur,
S., Saroa, R., and Aggarwal, S. (2015) ketamine-related adverse effects are uncommon in
patients who have general anesthesia. Adverse effects are more likely to be seen in patients who
receive bolus doses greater than 2 mg/kg, rapid administration or infusion rate greater than 2.5
mg/kg/min (Kaur et al., 2015).
Perioperative dosing.
Several completed studies have discussed the correct way to administer ketamine during
surgery to decrease postoperative opioid requirements. Some studies focus on giving a bolus of
ketamine at the beginning of surgery, some administer an infusion throughout, and others give
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both a bolus and infusion. The one thing that is consistent is the dose of ketamine administered
must be in a sub-anesthetic range to provide analgesic therapy.
According to Miller et al. (2015), ketamine administration in small doses decreases
postoperative analgesic consumption by 33 percent. They state an infusion rate of 0.15-0.25
milligram/kilogram or a total dosage of 20-60 milligram perioperatively is adequate to provide
this analgesic effect. An added benefit of decreased opiate use is reduced opiate side effects.
Remerand et al. (2009) conducted a randomized, double-blind, controlled clinical trial
that included 154 patients undergoing total hip arthroplasty. In this study, patients were
administered both a bolus and infusion of saline or ketamine. Patients who received the ketamine
bolus and infusion intra-operatively were found to have decreases in all of the following postoperatively: morphine consumption at 24 hours, walking assistance at 30 days, and hip pain
while at rest at 180 days.
A literature review conducted by Jougelet-Lacoste, La Colla, Schilling and Chelly (2015)
concluded that low-dose intravenous ketamine reduces opioid consumption by 40% and lowers
pain scores following surgery. Low-dose intravenous ketamine was defined as a bolus of < 1
mg/kg and/or an infusion of 1.2 mg/kg/hr. These clinical trials included a total of 2,482 patients
with 1,403 who received ketamine. Jougelet-Lacoste et al. (2015) did not find any major
complications when the ketamine was administered at sub-anesthetic doses.
Both Arikan, Aslan, Horasanh and But (2016) and Menigaux, Fletcher, Dupont,
Guignard, Guerimund and Chauvin (2000) found that small-dose intraoperative ketamine
decreased the amount of morphine required in the PACU and 24 hours after surgery. Another
randomized, double-blind, controlled clinical trial looked at using a ketamine infusion,
specifically, and found that these patients analgesia was effective in the post-operative period
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(Kaur, Saroa & Aggarwal, 2015). These patients were given a 0.2 mg/kg ketamine bolus
intravenously followed by an infusion of 0.1 mg/kg/hr for an open cholecystectomy. They found
that intraoperative infusion of low-dose ketamine provided effective analgesia for the first 6
hours in the postoperative period. The opioid-sparing effect of ketamine was observed to be
useful for narcotic-tolerant patients.
Loftus et al. (2010) conducted a randomized, double-blind controlled study, which
showed a decrease in opiate usage for 48 hours following surgery. The main difference between
this study and the ones previously listed is the inclusion criteria required that the patients had a
history of chronic pain with daily opiate use. This study also found that ketamine may reduce
pain intensity. These patients were given a 0.5 milligram/kilogram ketamine bolus intravenously
followed by an infusion of 10 microgram/kilogram/hour infusion.
A systematic review completed by Himmelseher & Duriex (2005) was completed to
examine the perioperative use of ketamine as an adjunct to general anesthesia and postoperative
pain therapy. A total of 10 trials met inclusion criteria. Surgeries were described as being painful
or less painful. A major visceral surgery was considered a painful surgery with a lumbar spine
surgery being less painful. An initial bolus of 0.2 mg/kilogram intravenous ketamine for less
painful surgeries and a bolus of 0.35 mg/kilogram for a painful surgery was administered prior to
incision, followed by a 200-400 mcg/kilogram/hour infusion or a 0.1-0.2 milligram/kilogram
bolus every 30 minutes was sufficient as an analgesic adjunct (Himmelseher, S. & Duriex, M.,
2005).
Conclusion
In conclusion, the majority of recent research suggests perioperative ketamine use to be
an excellent adjunct for postoperative analgesia and decreased opioid consumption. Ketamine
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has been shown to supplement post-operative pain management in all patients, including chronic
pain patients. In the aforementioned case study, ketamine was administered to a patient with a
history of chronic pain throughout a laparoscopic surgery with minimal opioid requirement
immediately post-operatively. It is impossible to state that the decreased post-operative opioid
requirements are solely due to the ketamine administered, but the research supports this.
Literature supports intraoperative ketamine with sub-anesthetic dosing to be beneficial
for all patients in decreasing post-operative opioid requirements. More research is needed to
determine the ideal dose, but there does seem to be consistency with a ketamine bolus of less
than or equal to 0.5mg/kg with or without an infusion.
Adequate pain management in patients with and without chronic pain is imperative in
healthcare today. Multi-modal analgesia and decreasing opioid requirements in patients plays a
considerable role in reducing opioid use overall. Anesthesia providers play a central role in pain
management in many patients and would benefit from additional knowledge in ketamine
administration.
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Appendix A
Introduction
Intraoperative Ketamine to Reduce
Postoperative Opioid Consumption in
Chronic Pain Patients
Allyssa Wutzke, SRNA

• Chronic pain is an epidemic in the United
States, resulting in an increased number of
prescribed opioids. Medical professionals are
being encouraged to decrease opioid
prescriptions.
• Chronic pain patients who have a surgical
procedure and are currently prescribed an
opioid experience markedly higher
postoperative pain.
(Chapman et al., 2011)

Introduction continued

Case Information

• NMDA receptors contribute to the pain felt after
tissue injury and can cause increased pain
perception.
• Ketamine binds to the NMDA receptors and
blocks this effect reducing the patient’s pain
postoperatively
• Ketamine’s usefulness in the perioperative setting
is promising

•
•
•
•
•

Diagnostic laparoscopy
29 year old female
99 kilogram – BMI 38.63
ASA II
Allergies to ketorolac and morphine

– It is an analgesic and an anesthetic
– Decreases opioid requirements
(Nagelhout & Plaus, 2014)

Pre-operative Evaluation
• Past Medical History
– ovarian cyst, chronic pelvic pain

• Surgical History
– cholecystectomy, cervix biopsy, colposcopy, ovarian
cystectomy

• Pre-op VS
– BP: 126/82 HR: 83 RR: 18 T: 36.7C O2: 99% RA

• Pertinent labs
– negative urine pregnancy

• Airway evaluation
– Mallampati classification II, thyromental distance less than
3 fingerbreadths, full neck range of motion

Anesthetic Course
• Pre-induction
– 2mg midazolam IV
• Induction
– 100mcg Fentanyl IV
– 60mg Lidocaine IV
– 200mg Propofol IV
– 60mg Rocuronium IV
– 50mg Ketamine (0.5mg/kg bolus) IV
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Anesthetic Course

PACU

• Maintenance
– 1.8-2.4% Sevoflurane
– 2 g Cefazolin IV
– 6 mg Dexamethasone IV
– 10 mcg/kg/min Ketamine IV infusion
– 100 mcg Fentanyl IV with incision

• Patient complained of moderate pain and was
given 75mcg Fentanyl IV.
• Patient was discharged home with 1/10
abdominal pain.
• No adverse effects noted while in PACU.

• Emergence
– 0.6 mg Glycopyrrolate IV
– 3 mg Neostigmine IV
– 4 mg Ondansetron IV

1200mL LR total EBL minimal

Chronic Pain

Chronic Pain continued

• Chronic pain is defined as pain that lasts longer than three
months or beyond the normal healing time of an injury
(Nagelhout & Plaus, 2014)

• Acute pain turns into chronic pain when peripheral damage
and tissue inflammation switch to more prominent central
nervous system mechanisms.
• Changes can also occur directly to nerve endings when
nerve injury is present.
– Regenerated and damaged nerves also have reduced
thresholds, rendering them responsive to non-noxious stimuli

• Chronic pain is associated with chronic inflammation.
– Causing hyperexcitability and sensitization of second-order
neurons in the dorsal horn
(Reddi & Curran, 2014)

• Central sensitization
– Ongoing nociceptive input may cause an increase in
excitability of neurons in the central nervous system
– May manifest as hyperalgesia or allodynia
– Wind-up occurs with repeated activation of C fibers
and is due to the action of glutamate at NMDA
receptors.
(Reddi & Curran, 2014)

• NMDA receptors also contribute to central
sensitization and chronic pain
– Due to up-regulation of second messengers causing
hyperexcitability of NMDA receptors
(Steeds, 2015)

NMDA Receptor

NMDA Receptor continued

• N-methyl-D-aspartate (NMDA) receptors are glutamategated cation channels with high calcium permeability
• Found at most excitatory synapses in the post-synaptic
membrane of a neuron
• Present on most cells of the central nervous system,
especially those that participate in nociception

• Glutamate is the major excitatory
neurotransmitter in CNS

(Mion & Villevieille, 2013)

• Magnesium blocks NMDA receptor activation in a voltagedependent manner
– At resting membrane potential, the receptor remains blocked.
With membrane depolarization, the magnesium block is
relieved
(Nagelhout & Plaus, 2014)

– It activates NMDA receptors by occupying two
binding sites of GluN2 subunits
(Vytlicky et al., 2013)

– NMDA receptor activation requires glutamate
presence and binding along with depolarization of
postsynaptic membrane to unseat the
magnesium
(Bennett, 2000)
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Ketamine

Ketamine continued

• Structurally related to phencyclidine
• Has two enantiomers: S(+)ketamine and R(-)ketamine.
• Ketamine is bioavailable by intravenous, intramuscular,
transnasal, rectal, and oral routes
• Lipid soluble and not highly protein bound

• Works on NMDA, opioid, noradrenergic, nicotinic and
muscarinic receptors

– Rapid uptake in highly perfused areas first
– The onset of action after intravenous administration is 30
to 60 seconds and duration of 10 to 15 minutes

• Ketamine is metabolized by cytochrome P-450
enzymes by demethylation to norketamine
(Barash et al., 2017)

(Miller et al., 2015)

• Binds to an intrachannel site on the NMDA receptor
referred to as the phencyclidine site (this binding decreases
channel opening time)
• It also works on a second site in the hydrophobic domain of
the NMDA receptor to decrease the frequency of channel
opening
– By blocking these receptors, the medial thalamic nuclei,
responsible for preventing afferent signals of pain perception to
the thalamus and cortex, is depressed
– NMDA-receptor antagonists suppress central sensitization
(Miller et al., 2015)

Ketamine continued

Perioperative Dosing

• Causes "dissociative anesthesia” due to a
functional dissociation between thalamoneocortical and limbic systems which allow
sensory inputs to reach receiving areas but fail
to be observed

• Miller et al. (2015) states ketamine administration in
small doses decreases postoperative analgesic
consumption by 33 percent

– It depresses neuronal function in the cerebral cortex
and thalamus while simultaneously activating the
limbic system

• Ketamine prevents "windup," especially if the
NMDA receptor was already opened by
glutamate
(Mion & Villevieille, 2013)

– Infusion rate of 0.15-0.25 mg/kg or a total dosage of 20-60
mg perioperatively is adequate to provide this analgesic
effect.

• Remerand et al. (2009) conducted a randomized,
double-blind, controlled clinical trial
– Included 154 patients undergoing total hip arthroplasty
– Given both a bolus and infusion of saline or ketamine.
– Patients who received the ketamine bolus and infusion
intra-operatively were found to have decreases in all of the
following post-operatively: morphine consumption at 24
hours, walking assistance at 30 days, and hip pain while at
rest at 180 days.

Perioperative Dosing continued

Perioperative Dosing continued

• A literature review conducted by JougeletLacoste, La Colla, Schilling and Chelly (2015)
concluded

• Studies by Arikan, Aslan, Horasanh and But (2016) and
Menigaux, Fletcher, Dupont, Guignard, Guerimund and
Chauvin (2000)

– low-dose intravenous ketamine reduces opioid
consumption by 40%
– lowers pain scores following surgery
– Low-dose intravenous ketamine was defined as a
bolus of < 1 mg/kg and/or an infusion of 1.2 mg/kg/hr
– These clinical trials included a total of 2,482 patients
with 1,403 who received ketamine
– did not find any major complications when the
ketamine was administered at sub-anesthetic doses

– small-dose intraoperative ketamine decreased the amount of
morphine required in the PACU and 24 hours after surgery.

• Kaur, Saroa and Aggarwal (2015) conducted a randomized,
double-blind, controlled clinical trail
– Patients were given a 0.2 mg/kg ketamine bolus followed by an
infusion of 0.1 mg/kg/hr for an open cholecystectomy.
– intraoperative infusion of low-dose ketamine provided effective
analgesia for the first 6 hours in the postoperative period.
– the opioid-sparing effect of ketamine was observed to be useful
for narcotic-tolerant patients.
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Perioperative Dosing continued

Perioperative Dosing continued

• Loftus et al. (2010) conducted a randomized,
double-blind controlled study

• A systematic review completed by Himmelseher &
Duriex (2005)
– Examined the perioperative use of ketamine as an adjunct
to general anesthesia and postoperative pain therapy.
– Surgeries were described as being painful or less painful. A
major visceral surgery was considered a painful surgery
with a lumbar spine surgery being less painful.
– Bolus ranged from 0.2-0.35 mg/kg depending on
anticipated pain of surgery followed by infusion of 200-400
mcg/kg/hr infusion or 0.1-0.2 mg/kg bolus every 30
minutes
– These doses were deemed sufficient as an analgesic
adjunct

– Showed a decrease in opiate usage for 48 hours
following surgery
– Inclusion criteria required that the patients had a
history of chronic pain with daily opiate use
– Found that ketamine may reduce pain intensity
– Given a 0.5 mg/kg ketamine bolus IV followed by a
10mcg/kg/min infusion

Recommendations

Conclusion

• Ketamine should be used to supplement postoperative pain management in chronic pain
patients
• More research needed to determine ideal
dosing

• Case Study

– There does seem to be consistency in the current
literature with a ketamine bolus of 0.2-0.5mg/kg
followed by an infusion or hourly dosing

– 0.5 mg/kg bolus given at induction followed
by 10mcg/kg/min infusion perioperatively
– Within the ranges noted above

• Literature supports sub-anesthetic dosing
beneficial for chronic patients in decreasing
post-operative opioid requirements.

• Minimal or no side effects noted in literature at these
doses
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